Seer, Inc. (SEER)

2,2400 +0,0800 (+3,70%) Börsenschluss: 04:00PM EDT

Seer, Inc.

3800 Bridge Parkway
Suite 102
Redwood City, CA 94065
United States
650 453 0000
https://seer.bio

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 147

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Omid C. Farokhzad M.D., Ph.D.	Founder, CEO, & Chair of the Board of Directors	1,18M	N/A	1969
Mr. David R. Horn	President,Treasurer & CFO	661,64k	N/A	1968
Ms. Elona Kogan Esq., J.D.	Chief Legal Officer,General Counsel & Secretary	575,86k	N/A	1969
Mr. Joe Laws	Chief Technology Officer and Co-Founder	N/A	N/A	N/A
Kenny Ross	Chief Operations & Product Officer	N/A	N/A	N/A
Ms. Marissa Dixon	Chief People Officer	N/A	N/A	N/A
Dr. Serafim Batzoglou Ph.D.	Chief Data Officer	N/A	N/A	N/A
Mr. Martin Goldberg Ph.D.	Senior Vice President of Development	N/A	N/A	N/A
Dr. Asim Siddiqui Ph.D.	Senior Vice President of Research & Tech Development	N/A	N/A	N/A
Dr. Christopher E. Mason Ph.D.	Member of Scientific Advisory Board	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

Corporate Governance

Seer, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 10, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.